Search

everythinglearnresearchcommunity

for

Search:↓

TNF-α blockers and IL inhibitors improve symptoms in most patients with severe scalp condition, but more research is needed.

Anti-TNF-α therapy may increase the risk of developing alopecia areata, especially in those with a history of autoimmune disease.

The document suggests a personalized treatment plan for alopecia areata based on the patient's age and hair loss severity, using a range of therapies ranked by effectiveness and safety.

New treatments for Dissecting cellulitis show promise, but more research is needed to understand the disease and establish a standard treatment plan.

Biologic treatments for Crohn's disease and ulcerative colitis can cause skin problems, and doctors should adjust treatment if these occur.

IBD patients treated with TNF antagonists may develop autoimmune alopecia areata, with severe cases less likely to improve.

Etanercept improved arthritis and psoriasis but caused hair loss, which healed after switching to sulfasalazine.

Hidradenitis suppurativa is a chronic skin condition causing painful lumps and scarring, often triggered by smoking and obesity, and requires varying treatments based on severity.

Hidradenitis Suppurativa is a chronic skin condition best treated early with surgery for better outcomes and less recurrence.

Psoriasis patients are more likely to develop alopecia areata due to complex autoimmune interactions.

Scalp psoriasis can cause different types of hair loss, with some patients developing permanent hair loss, and treatment may be stopped due to skin reactions.

TNFα and interleukin-1 blockers reduce skin inflammation from EGFR antibody therapy.

TNFα and interleukin-1 blockers reduce skin inflammation from EGFR antibody therapy.

Etanercept may not prevent alopecia areata from coming back.

Minor injuries to hair follicles can stimulate hair growth in mice by increasing a specific protein.

A woman developed hair loss after starting a treatment with adalimumab, suggesting this medication might cause hair loss.

Minor skin injuries can boost hair growth by increasing TNF-α.

Keratinocytes contribute to hidradenitis suppurativa by causing inflammation and worsening the condition.

TNF-alpha inhibitors can cause various immune-related skin issues.

TNF-α inhibitors may cause complete hair loss in some patients with ankylosing spondylitis.

Anti-IL-12/IL-23 antibody therapy effectively treats psoriasiform skin lesions in IBD patients.

Immunosuppressive and anti-TNF therapies in IBD patients can increase the risk of skin cancer and cause various skin issues.

Any drug can cause skin reactions, but antibiotics, NSAIDs, and psychotropic drugs are more common, with some reactions being life-threatening.

Hidradenitis Suppurativa is likely an autoinflammatory disease, and better understanding its causes could improve treatments.

Biologic agents can be effective for rheumatic diseases but have risks like infections and require careful monitoring and patient information.

Some drugs used to treat inflammation may cause hair loss.

Shrinking of oil glands in the skin is a key sign of hair loss linked to TNF inhibitor drugs and may improve if the treatment is stopped.

Blocking interferon-gamma might help treat various autoimmune diseases.

New treatments for vitiligo may focus on protecting melanocyte stem cells from stress and targeting specific pathways involved in the condition.

Some medications for inflammation can cause a condition with scalp rashes and hair loss, often linked to Crohn's disease, and may require treatment changes to prevent permanent hair loss.